Ογκολογία Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial 28/09/2024 time to read 2 min read
Ογκολογία Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial 01/11/2023 time to read 3 min read
Ογκολογία Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer 03/06/2023 time to read 2 min read
Ογκολογία Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study Authors: Silvia Novello et al. 10/04/2023 time to read 2 min read
Ογκολογία Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study Authors: Marina C Garassino et al. 10/04/2023 time to read 2 min read
Ογκολογία Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial 23/10/2022 time to read 3 min read
Ογκολογία Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50 Authors: Martin Reck et al. 20/07/2021 time to read 2 min read
Ογκολογία Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 Authors: D Rodríguez-Abreu et al. 01/07/2021 time to read 2 min read
Καρδιολογία Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial Authors: Marius M Hoeper et al. 01/06/2021 time to read 3 min read
Ογκολογία A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 Authors: Luis Paz-Ares et al. 01/10/2020 time to read 2 min read
Ογκολογία Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer Authors: Shirish Gadgeel et al. 10/05/2020 time to read 2 min read
Ογκολογία Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial Authors: Marina C Garassino et al. 01/03/2020 time to read 3 min read